Biotech Values

[alfabeta]

OS question EXEL must answer
It is a dual(or multiple) inhibitor. In the MTC trial, why did it has a very long PFS, not OS?
from yahoo msg brd.

In his study, Dr. Raghu Kalluri found out with sole EGFR inhibitors "a fivefold increase in activation of Met, a receptor molecule that promotes cell migration and growth". And, "Additional experiments showed that combining pericyte-depleting drugs with the Met-inhibiting drug helped suppress EMT and metastasis".
I don't understand in EXAM, PFS didn't reflect on OS, 4mo vs 11mo was too big a difference for anything like OS data are not matured. Our MET inhibition is not strong enough or there is other path revengefully come back?